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Abstract
Background: The mechanism underlying the ability of fibroblasts to contract a collagen gel matrix is largely
unknown. Fibroblasts from scarred (lesional) areas of patients with the fibrotic disease scleroderma show enhanced
ability to contract collagen relative to healthy fibroblasts. Thrombospondin 1 (TSP1), an activator of latent
transforming growth factor (TGF)b, is overexpressed by scleroderma fibroblasts. In this report we investigate whether
activation of latent TGFb by TSP1 plays a key role in matrix contraction by normal and scleroderma fibroblasts.
Methods: We use the fibroblast populated collagen lattices (FPCL) model of matrix contraction to show that
interfering with TSP1/TGFb binding and knockdown of TSP1 expression suppressed the contractile ability of normal
and scleroderma fibroblasts basally and in response to TGFb. Previously, we have shown that ras/mitogen-activated
protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) mediates matrix contraction basally and in
response to TGFb.
Results: During mechanical stimulation in the FPCL system, using a multistation tensioning-culture force monitor
(mst-CFM), TSP1 expression and p-ERK activation in fibroblasts are enhanced. Inhibiting TSP1 activity reduced the
elevated activation of MEK/ERK and expression of key fibrogenic proteins. TSP1 also blocked platelet-derived
growth factor (PDGF)-induced contractile activity and MEK/ERK activation.
Conclusions: TSP1 is a key mediator of matrix contraction of normal and systemic sclerosis fibroblasts, via MEK/ERK.
Background
Scleroderma (systemic sclerosis (SSc)) is a chronic dis-
ease of unknown aetiology characterised by microvascu-
lar injury, autoimmune inflammatory responses, and
severe and often progressive fibrosis [1-3]. There is no
therapy for the fibrosis observed in SSc. SSc dermal
fibroblasts can be isolated and cultured readily, and will
retain their enhanced expression of type I collagen and
a smooth muscle actin, (a-SMA) [4-7]. Thus, examina-
tion of the molecular difference that may exist between
normal fibroblasts from healthy individuals and fibro-
blasts from ‘lesional’ areas of SSc patients would seem
to be an ideal system to yield valuable insights into the
pathogenesis of SSc. Although the molecular basis for
SSc is unclear, we have previously shown that fibroblast
from scarred (lesional) area of SSc patients show ele-
vated constitutive extracellular signal-regulated kinase
(ERK) activation and overexpress a cohort of profibrotic
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also known as CCN2), and the heparan sulfate contain-
ing proteoglycans (HSPGs) syndecan 2 and syndecan 4
[7,8]. As one of the extracellular modular glycoproteins,
thrombospondin (TSP)1 was also found to be highly
expressed in SSc dermal fibroblasts [9]. Significantly,
whereas non-lesional and lesional SSc fibroblasts pro-
duce similar amounts of type I collagen, lesional SSc
fibroblasts show markedly enhanced abilities to adhere
to and contract extracellular matrix [7]. The enhanced
contractile ability of lesional SSc fibroblasts was sup-
pressed by blocking HSPG biosynthesis, mitogen-
activated protein kinase kinase (MEK) or antagonising
transforming growth factor (TGF)b receptor type I
(activin-linked kinase 5 (ALK5)) [7,10]. Enhanced
activation of ERK was also observed in lesional SSc [7].
Moreover, heparan sulfate-dependent ERK activation
contributes to the overexpression of profibrotic proteins
and the enhanced contraction by lesional dermal sclero-
derma fibroblasts of their extracellular matrix [11]. We
have begun to dissect the role that individual proteins
play in fibroblast activation; for example, the HSPG syn-
decan 4 is required both for basal and growth factor-
induced ERK activation in normal fibroblasts and for
the enhanced activation of ERK observed in lesional SSc
fibroblasts [7]. However, overall, the fundamental roles
of individual matrix proteins in SSc pathogenesis are lar-
gely unknown.
TGFb has long been hypothesised to be a major con-
tributor to pathological fibrotic diseases. As TGFb
induces fibroblasts to synthesise and contract the extra-
cellular matrix (ECM), this cytokine has long been
believed to be a central mediator in wound healing and
fibrotic responses, including SSc [12]. Despite the fact
that enhanced ECM contraction and adhesion observed
in SSc fibroblasts depends on TGFb type I receptor
(ALK5) activity, the fundamental mechanism underlying
the contribution of TGFb to the fibrotic phenotype of
SSc is unclear as, in this cell type, ALK5 inhibition was
unable to reduce critical features of the myofibroblast
phenotype, such as a-SMA expression and stress fibre
formation [10]. The majority of the studies conducted
thus far has measured acute responses to TGFb and
suggest that TGFb alone is insufficient for sustained
fibrogenic responses [12,13]. Recently, we have shown
that TGFb signalling partially contributes to the fibrotic
phenotype of SSc fibroblasts, resulting from an exag-
geration of processes normally operating in cells [7,10].
However, so far relatively little is known about the
underlying cause of this exaggerated TGFb signalling
and how this might contribute to the enhanced contrac-
tile activity of SSc lesional fibroblasts.
TSP1, an extracellular modular glycoprotein secreted
by many cell types, is a component of the extracellular
matrix in remodelling tissues and can bind to different
matrix proteins and cell surface receptors, including
proteoglycans, non-integrin, and integrin receptors [14].
The latter include a3b1a n da5b3 integrin receptors
[15]. TSP1 also interacts with structural proteins such as
collagens, fibronectin, and laminins. These interactions
may present TSP1 to the cell surface, where it can med-
iate interactions between these proteins and their recep-
tors [14]. These abilities account for multifunctional
nature and sometimes contradictory functions of TSP1,
which include influencing platelet function, angiogen-
esis, tumour biology, wound healing, and vascular dis-
ease [16]. TSP1 may execute many of its functions
through its ability to activate TGFb in vitro and in vivo.
TSP1 binds the latency-associated peptide (LAP) of the
latent TGFb complex. Thrombospondin-LAP complex
formation involves the activation sequence of thrombos-
pondin 1 (KRFK) and a sequence (LSKL) near the
N-terminus of LAP that is conserved in TGFb [1-5].
The interactions of LAP with TSP1 through the LSKL
and KRFK sequences are important for thrombospon-
din-mediated activation of latent TGFb,s i n c eL S K L
peptides competitively inhibit latent TGFb activation by
TSP1 or other KRFK-containing peptides [17]. Providing
evidence of functional relevance of these observations to
fibrotic diseases, such as SSc, recombinant TSP1 promotes
fibroblast-mediated floating collagen gel contraction
induced by TGFb [18].
Consequently, much interest exists, from both clinical
and pharmaceutical points of view, in identifying not
only whether TSP1 can promote the pathogenesis of
fibrotic diseases such SSc, but also whether targeting
TGFb signalling by antagonising TSP1 might be useful
for treating these disorders. In this study, we hypothe-
sised that TSP1 may be an endogenous activator of
TGFb during contraction of extracellular matrix in nor-
mal and SSc fibroblasts. We used the fibroblast popu-
lated collagen lattices (FPCL) system of matrix
contraction to evaluate the contribution of TSP1 to the
contractile activity of normal and SSc fibroblasts both
basally and in response to TGFb.W es h o wt h a tu s i n g
TSP1 blocking peptide, or small interfering (siRNA)
recognising TSP1, affects the contractile activity of nor-
mal and SSc fibroblasts. Our results provide novel
insights into the underlying mechanisms behind matrix
contraction by fibroblasts and the exaggerated TGFb
signalling observed in the pathogenesis of SSc.
Methods
Cell culture
Briefly, cell culture was performed as previously
described [19,20]. Dermal fibroblasts from lesional
(clinically affected) areas of female patients with diffuse
SSc (duration of between 12 and 18 months) and
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and anatomically site-matched volunteers, after
informed consent and ethical approval was obtained. All
patients fulfilled the criteria of the American College of
Rheumatology for the diagnosis of diffuse SSc, as
defined by LeRoy et al. [21]. Fibroblasts were main-
tained in Dulbecco’s modified Eagle medium (DMEM)
(First Link, Birmingham, UK), 10% foetal bovine serum
(First Link, Birmingham, UK), 100 U/ml penicillin, and
100 mg/ml streptomycin, 5% CO2. Fibroblasts were sub-
cultured 1:4 at confluence. When appropriate, TSP1
blocking peptides (LSKL and an inert control peptide
SLLK), ERK inhibitor U0126 (10 μM, Promega), the
ALK5 inhibitor SB 431542 (10 μM, Tocris, Bristol, UK),
platelet-derived growth factor (PDGF) receptor inhibitor
Gleevec (2 mM, imatinib mesylate), or interferon (IFN)b
(5 ng/ml, Serono Pharmaceutical Research Institute,
Geneva, Switzerland) was added.
Western blot and immunofluorescence analysis
Fibroblasts within three-dimensional collagen matrices
following FPCL contraction or fibroblasts from mono-
layer culture were collected and lysed with 8 M urea
and 1% SDS sample buffer. Proteins were quantified
(Bradford, Bio-Rad, Hercules, California, USA), and
equal amounts of protein (25 μg) were subjected to
SDS/PAGE using 4% to 12% polyacrylamide gels (Invi-
trogen, Paisley, UK). Gels were blotted onto nitrocellu-
lose, and proteins were detected using anti-CCN2 (Santa
Cruz, Wembly, UK), anti a-SMA (Sigma, St Louis USA),
anti-syndecan 4, anti-a3a n da n t i - b5i n t e g r i n( Z y m e d ,
Paisley, UK), anti-thrombospondin 1 (TSP1) (Abcam,
Cambridge, UK), anti a-SMA (Sigma, St Louis USA),
anti p-SMAD3 (Cell Signalling, Paisley UK) and appro-
priate horseradish peroxidase (HRP)-conjugated second-
ary antibodies (Cell Signalling, Paisley UK) and an
enhanced chemiluminescence (ECL) kit (Amersham, Lit-
tle Chalfont, UK). Densitometry was performed using
Quantity One software (Bio-Rad, Hercules, California,
USA ). For immunofluorescence detection, cells were
fixed in 3% paraformaldehyde (15 min) and localisation
of proteins was detected as previously described [7].
Real-time PCR
Cells were serum-starved for 24 h and treated with or
without inhibitors, as indicated, for an additional 24 h.
Total RNA was isolated using Trizol (Invitrogen Paisley,
UK,)and the integrity of the RNA was verified by Agi-
lent bioanalyser. Total RNA (25 ng) was reverse tran-
scribed and amplified using TaqMan One-step master
mix and Assays on Demand primers (Applied Biosys-
tems, Carlsbed, California, USA) in 15 μl reaction
volumes with 6-carboxyfluorescein labelled TaqMan
MG probe. Signals were detected using the ABI Prism
7900 HT sequence detector (Perkin-Elmer-Cetus,
Vaudreuil, Canada). Triplicate samples were run, tran-
scripts, and expression values were standardised to values
obtained with control 28S RNA primers as previously
described using the ΔCt method [22].
FPCL
Measurement of contractile force generated within a
three-dimensional, tethered floating fibroblast-populated
collagen lattice was performed as described previously
[23,24]. Using 1 × 10
6 cells/ml of collagen gel (First
Link, Birmingham, USA), we measured the force gener-
ated across the collagen lattice with a culture force
monitor (CFM). This instrument measures the minute
forces exerted by cells within a collagen lattice over
24 h as fibroblasts attach, spread, migrate and differenti-
ate into myofibroblasts [25]. In brief, a rectangular fibro-
blast seeded collagen gel was cast and floated in
medium with 10% fetal calf serum (FCS), or in 2% FCS
when the effect of antagonising TGFb was examined.
The collagen gels were tethered to two flotation bars on
either side of the long edges, and, in turn attached to a
ground point at one end and a force transducer at the
other. Cell-generated tensional forces in the collagen gel
were detected by the force transducer and logged into a
personal computer. Graphical readings were produced
every 15 s providing a continuous measurement of force
(Dynes: 1 × 10
-5 N) generated [25].
Mechanical stimulation of both normal and SSc fibro-
blasts was achieved with the use of the multistation ten-
sioning-culture force monitor (mst-CFM) using this
system FPCLs were prepared as previously described,
placed into the mst-CFM and allowed to contract endo-
genously for 12 h prior to a further 12 h of mechanical
stimulation as previously described [26]. The cells used
in these experiments were passage matched; all control
and inhibition experiments were run in parallel.
Floating collagen gel contraction assay
Experiments were performed essentially as described
previously [7]. Briefly, 24-well tissue culture plates were
precoated with bovine serum albumin (BSA). Normal
and SSc lesional fibroblasts were treated with TGFb or
PDGF with or without ERK inhibitor U0126 (10 μM,
Promega, Madison, Winsconsin, USA), the ALK5 inhibi-
tor SB 431542 (10 μM ,T o c r i s ,B r i s t o l ,U K ) ,t h eP D G F
receptor inhibitor Gleevec (2 mM, imatinib mesylate),
or IFNb (5 ng/ml, Serono Pharmaceutical Research
Institute SA, Geneva, Switzerland) for 24 h. Pretreated
fibroblasts were suspended in MCDB medium (Sigma,
Paisley UK) and mixed with collagen solution (one part
0.2 M N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic
acid (HEPES), pH 8.0, four parts collagen (Vitrogen-100,
3 mg/ml) and five parts of MCDB × 2), yielding a final
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collagen. Collagen/cell suspension (1 ml) was added to
each well. After polymerisation, gels were detached from
w e l l sb ya d d i n g1m lo fM C D Bm e d i u mw i t hP D G F ,
TGFb or tumour necrosis factor (TNF)b. Contraction of
the gel was quantified by loss of gel weight and decrease
in gel diameter over a 24-h time period.
siRNA knockdown
Specific siRNA recognising TSP1 was purchased as a
pool of three predesigned siRNAs (siRNA#138861,
siRNA#12934 and siRNA#12845) alone with a recom-
mended control siRNA (Ambion, Warrington, UK).
Normal and SSc fibroblasts were transfected using Silen-
cer siRNA Transfection II Kit (Ambion, Applied Biosys-
tems, Warrington UK). Cells were transfected either
with control siRNA or control siRNA with TSP1 siRNA.
Western blot analysis with an anti-TSP1 antibody was
performed to check the efficiency of the siRNA to
reduce TSP1 protein expression. The contractile ability
of the cells was analysed as described above.
Results
Blocking TSP1 activation of latent TGFb with LSKL
peptide decreased the enhanced contractile activity of
fibrotic SSc fibroblasts
Both overexpression of TSP1 and elevated TGFb activity
can be found in SSc dermal fibroblasts [7,9,10]. We
wanted to evaluate whether TSP1 mediates matrix con-
traction in fibroblasts by assessing if interfering with
b i n d i n go fT S P 1t oT G F b suppresses the basal and
TGFb-induced contractile activity of normal or SSc
fibroblasts. LSKL peptides (selective antagonists of
TSP1, which specifically interfere with the ability of
TSP1 to activate TGFb) and SLLK peptide (an inert
control) [27] were used in the FPCL assay of matrix
contraction. Fibroblasts in the three-dimensional FPCL
system generate contractile forces, similar those found
in scars and in granulation tissue undergoing matrix
remodelling during normal and pathological situations
[23,24,28]. Healthy and SSc fibroblasts were pretreated
with TSP1 blocking peptides (LSKL) or control peptide
(SLLK) for 5 days and then transferred to a culture
force monitor (CFM) and forces exerted by cells within
t h ec o l l a g e nl a t t i c eo v e r2 4hi n2 %s e r u m ,b o t hi nt h e
presence and absence of added TGFb [27] were mea-
sured and recorded. At the end of the culture period,
the LSKL peptide reduced the contractile force gener-
ated by SSc fibroblasts by about 25%, and also signifi-
cantly blocked the TGFb-induced contractile force in
both normal and SSc fibroblast groups, by 24% and
41%, respectively. The LSKL peptide also showed
reduced the basal contractile force generated by normal
fibroblasts by approximately 14% (Figure 1). These
results suggested the intriguing notion that activation of
endogenous latent TGFb played a key role in ECM con-
traction by both healthy and fibrotic fibroblasts.
Blocking TSP1 activation of TGFb with LSKL peptide
impacted on the mitogen-activated protein kinase (MAPK)
signalling pathways and reduced matrix protein
expressions in SSc fibroblasts
Lesional dermal SSc fibroblasts are characterised by the
markedly enhanced ability to adhere to and contract
extracellular matrix [7]. To further investigate the
mechanism underlying TSP1-dependent contractile
activity, fibroblasts in fully contracted FPCL gel samples
(that is, 24 h post culturing in the FPCL system) were
analysed by western blotting to evaluate whether in this
context TSP1 blocking peptide reduced expression of
matrix proteins and the activation of procontractile sig-
nalling pathways. Western blot analysis revealed that the
TSP1 blocking peptide reduced expression of profibrotic
proteins such as a-SMA, integrin a3, integrin b5, and
the activation of p-ERK and p-p38 kinase in SSc fibro-
blasts (Figure 2a). Moreover, TGFb-induced matrix
gene expression and ERK and p38 phosphorylation in
Figure 1 The enhanced contractile activity of fibrotic systemic
sclerosis (SSc) fibroblasts can be moderated by blocking
thrombospondin 1 (TSP1) activation of latent transforming
growth factor (TGF)b with a LSKL peptide. Normal and SSc
fibroblasts were pretreated for 5 days with LSKL peptide, a selective
antagonist of TSP1. Cells were then suspended in a collage lattice
prior to contraction in the culture force monitor (CFM). Blocking the
TSP1 function with the LSKL peptide reduced the force generated
by both normal and SSc cells even after treatment with TGFb. Note
that LSKL peptide also reduced the basal contractile force in normal
fibroblasts groups. SLLK peptide was used as an inert control.
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Figure 2 Blocking thrombospondin 1 (TSP1) signalling with a LSKL peptide reduces matrix protein expression in both systemic
sclerosis (SSc) and normal fibroblasts. (a) Following contraction in the culture force monitor (CFM) the LSKL peptide-treated fibroblasts were
prepared for western blot analyse to determine the protein expression levels. LSKL peptide reduced the expression of some profibrotic proteins
and mitogen-activated protein kinase (MAPK) activities in SSc fibroblasts. (b) Immunofluorescence staining demonstrated that the LSKL peptide-
treated SSc fibroblasts demonstrated a reduction in a smooth muscle actin (a-SMA) stress fibres and reduced the presence of p-extracellular
signal-regulated kinase (ERK).
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(Figure 2a).
TGFb causes fibroblasts to differentiate into myofibro-
blasts, the a-SMA containing cells that are involve in the
contraction processes in wound contraction and fibrosis
tissue in vivo [24,29,30]. ERK activation contributes to
the enhanced contraction by lesional dermal scleroderma
fibroblasts by promoting the assembly of a-SMA stress
fibres [11]. To extend our data obtained by western blot
analyses indicating that LSKL peptide reduced ERK acti-
vation and a-SMA expression in SSc fibroblasts, we
employed indirect immunofluorescence analysis to show
that a 24-h treatment of SSc fibroblasts with LSKL pep-
tide reduced the appearance of a-SMA stress fibres and
the intense p-ERK staining, both key features characteris-
ing SSc fibroblasts, Moreover, the LSKL peptide also
blocked TGFb-induced a-SMA expression and p-ERK
activity in normal and SSc fibroblasts (Figure 2b).
TSP1 is a key mediator promoting SSc fibroblast
contraction
Based on the above findings, it needed to be elucidated
whether TSP1 could directly mediate the enhanced con-
tractile activities of SSc fibroblasts. To perform this ana-
lysis, we reduced TSP1 protein expression in normal
and SSc fibroblasts using siRNA recognising TSP1. Wes-
tern blot analysis was used to assess the ability of siRNA
recognising TSP1, compared to control siRNA, to
reduce TSP1 protein expression levels (Figure 3b). The
contractile ability of TSP1 knockdown cells was analysed
using the CFM system. We found that the contractile
ability of SSc fibroblast was reduced by 16% at the 24th
hourly time point after TSP1 expression knockdown; in
addition, TGFb-induced contractility of both normal
and SSc fibroblasts were diminished by 18% and 29%,
respectively, at the 24-h time point. The basal contracti-
lity of normal fibroblasts was reduced 19% at this time
point (Figure 3a). Western blot assays were also per-
formed with fibroblasts treated with TSP1 siRNA (Fig-
ure 3b). After TSP1 knockdown in fibroblasts from
normal and SSc patients, p-ERK activation was reduced,
concomitant with decreased expression of integrin a3.
Consistent with prior data using an ALK5 inhibitor [10],
extremely modest reduction of a-SMA and integrin b5
were observed. Expression of CCN2 and syndecan 4 was
not altered in normal and SSc fibroblasts confirming
previous evidence that basal expression of these proteins
is independent of the TGFb pathway [11].
TSP1 expression and p-ERK activation were enhanced by
the external mechanical force loading stimulation
It has been suggested that TSP1 plays a significant role in
wound healing [30]. Fibroblasts loaded by biomechanical
forces within the three-dimensional FPCL system
remodel their matrix resulting in potent differentiation
into myofibroblasts similar to that observed in wound tis-
sue and pathological scarring [28]. As our previous data
suggested that TSP1-mediated activation of TGFb played
a key role in matrix contraction by normal and fibrotic
fibroblasts, we wondered if fibroblast-induced ECM con-
traction itself was sufficient to induce TSP1 expression.
Thus, fibroblasts from normal and SSc patients were
mechanically loaded to a magnitude similar to that seen in
skin wounds [31-35]. During mechanical loading, cells
within the FPCL system went through normal gel contrac-
tion for 12 h, after which cyclical mechanical forces were
exerted on cells controlled by a computer. Each cycle con-
sisted of force loading for 9 min followed by a 15-min rest-
ing phase prior to unloading for an additional 9 min
followed by a further 15-min resting phase. Cycles were
repeated 15 times for an additional 12 h (Figure 4a). ERK
activation contributes to the overexpression of fibrotic
proteins and the enhanced contraction by lesional dermal
scleroderma fibroblasts [11]. Therefore, after force-loaded
gel contraction, TSP1 expression and p-ERK activation
were assessed by western blotting. We found that TSP1
expression and p-ERK activation were significantly
increased in force-loaded fibroblasts isolated from both
normal individuals and SSc patients (Figure 4b). TSP1
expression is therefore regulated by contractile activity of
fibroblasts within the three-dimensional FPCL model.
TSP1 is induced by PDGF and TGFb during fibroblast-
mediated matrix contraction
Our previous research had demonstrated that TGFb
enhanced contractile ability of fibroblasts partly depends
on ERK activation [11]. Inhibiting the TGFb type I
(ALK5) receptor reduced the contractility of fibroblasts,
but not a-SMA expression and stress fibre formation
[7,10]. Conversely, the PDGF/c-abl inhibitor Gleevec
reduced ECM contraction and a-SMA expression [11].
Previously, it was shown that the antifibrotic effect of
interferon b in lung fibrosis occurred via inhibiting
TGFb activation and decreasing TSP1/2 expression [36].
Our current data showed that TSP1 contributed to the
ability of fibroblasts to contract matrix and phosphory-
late ERK. To further confirm the relationship between
MEK/ERK signalling pathway and TSP1 function on the
contractile ability of fibroblasts, normal fibroblasts were
treated for 24 h with or without TGFb in the presence
or absence of SB431542 (ALK5 inhibitor), U0126 (MEK
inhibitor) or IFNb prior to performing a floating gel
contraction assay. A floating collagen gel contraction
assay was used to show that TGFb-induced contractile
ability was significantly reduced by IFNb as well as
SB431542 and U0126 (Figure 5a). Following floating gel
contraction, the fibroblasts in floating gel samples
were analysed by western blot. Our results showed that
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SB431542 (ALK5 inhibitor), U0126 (ERK inhibitor) or
IFNb. It is interesting to note that TGFb-induced p-ERK
activation also was inhibited by SB431542 and IFNb (Fig-
ure 5b). PDGF can markedly potentiate tissue repair in
vivo and also may stimulate cells to express growth factors
such as TGFb [36,37]. The expression of TSP1 in vitro can
be induced by platelet-derived growth factor (PDGF) [38].
Therefore, normal fibroblasts were also treated with PDGF
or the PDGF receptor inhibitor Gleevec prior to conduct-
ing collagen gel contraction assays. We found that PDGF-
induced contractile ability, ERK phosphorylation and
TSP1 expression in a Gleevec-sensitive fashion (Figure 5a,
b). Moreover, reverse transcription (RT)-PCR analysis of
mRNAs extracted from fibroblasts subjected to ECM con-
traction revealed that the TSP1 mRNA levels were altered
in a manner paralleling our TSP1 protein analyses (Figure
5c). All these results indicated that TSP1 is induced during
PDGF-mediated and TGFb-mediated matrix contraction
by normal fibroblasts.
Overexpression of TSP1 in SSc fibroblasts is due to
endogenous TGFb and PDGF via a MEK/ERK-dependent
mechanism
Our previous work showed that TGFb receptor type I
(ALK5) and MEK/ERK contribute to the elevated
Figure 4 Thrombospondin 1 (TSP1) expression and p-
extracellular signal-regulated kinase (ERK) activation in
fibroblasts is enhanced by applied mechanical stimulation. (a).
Cells were allowed to contract the collagen matrix for 12 h prior to
the application of an external load for a further 12 h. (b) Following
gel contraction and mechanical loading cells were recovered from
the gels and the levels of protein expression determined by
western blot. TSP1 expression and p-ERK activation were
significantly increased following mechanical stimulation in both
normal and systemic sclerosis (SSc) fibroblasts.
(A)
(B)

Figure 3 Knockdown thrombospondin 1 (TSP1) expression through small interfering (si)RNA transfection alters the contractile
characteristics and protein expression in both normal and systemic sclerosis (SSc) fibroblasts. (a) The contractile ability of SSc and
normal fibroblasts were reduced following siRNA transfection. (b) Western blot demonstrating a reduction in protein expression following siRNA
transfection.
Chen et al. Fibrogenesis & Tissue Repair 2011, 4:9
http://www.fibrogenesis.com/content/4/1/9
Page 7 of 12A

B
C
Figure 5 Thrombospondin 1 (TSP1) contributed to platelet-derived growth factor (PDGF) and transforming growth factor (TGF)b-
induced contractile activation in normal fibroblasts via mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated
kinase (ERK) signalling pathways. (a) Normal fibroblasts were treated overnight with or without TGFb or PDGF, plus the antagonists of activin-
linked kinase 5 (ALK5), ERK and PDGF, and interferon (IFN)b prior to performing a floating gel contraction assay. TGFb-induced contractile ability
was significantly reduced by IFNb as that by SB431542 and U0126 in normal fibroblasts. PDGF-induced cell contractility was impaired by PDGF
receptor inhibitor (Gleevec). (b) Following floating gel contraction, the fibroblasts in floating gel samples were analysed by western blotting.
TGFb-induced TSP1 expression and p-ERK activations were inhibited by SB431542, U0126 or IFNb. PDGF induced the overexpression of TSP1
inhibited by Gleevec, which also accompanied a retrained reaction for PDGF-induced p-ERK activation in normal fibroblasts. (c) The mRNAs from
the fibroblasts in these floating gel samples were also assayed by reverse transcription (RT)-PCR. The TSP1 gene expression levels altered in a
similar manner to the TSP1 protein expression level within the corresponding groups.
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we wanted to further clarify whether the overexpression
of TSP1 in SSc fibroblasts is impacted by blocking endo-
genous TGFb and PDGF signalling, SSc lesional fibro-
blasts were treated overnight with SB431542 (ALK5
inhibitor), U0126 (MEK inhibitor) or IFNb.T S P 1p r o -
tein and mRNA expression were assayed with western
blotting and RT-PCR. Our results showed that mRNA
and protein expression of TSP1 in SSc fibroblasts were
inhibited by antagonists of ALK5 and MEK, as well as
IFNb. SSc fibroblasts treated with Gleevec also showed
reduced TSP1 mRNA and protein (Figure 6). Collec-
tively, these results indicated that the enhanced contrac-
tile ability of SSc dermal fibroblasts depends on TSP1
induction downstream of endogenous TGFb and PDGF
through MEK/ERK. Moreover, our data provide clear
evidence that TSP1 plays a key role in mediating the
fibrotic phenotype observed in SSc.
Discussion
The contraction processes in wound and fibrotic tissue
mainly depend on a specialised form of fibroblasts
known as myofibroblasts, which express the procontrac-
tile protein a- S M A .I ti sa l s ow e l lk n o wt h a tan u m b e r
of integrins are responsible for cell contraction within
different types of cells [39,40]. Our previous data had
found that dermal fibroblasts from SSc lesions are char-
acterised by enhanced contractile ability of SSc fibro-
blasts and expression of a cohort of overexpress
profibrotic genes, including a-SMA and integrins [7,10].
TGFb1 is a key factor in mediating both in fibroblasts’
participation in wound repair and in a promoting patho-
logical fibrosis, including SSc. Treatment of fibroblasts
with TGFb results in their differentiation into myofibro-
blasts and also stimulates their production of extracellu-
lar matrix, and adhesive proteins such as integrins
[7,41]. In monolayer culture, TGFb is partially responsi-
ble for the phenotype of lesional SSc fibroblasts [7,10].
However, it remains unclear whether activation of TGFb
signalling plays a role in ECM contraction in three-
dimensional models of contraction. The data presented
in this investigation shown that TSP1 is tightly linked
with the enhanced contractility of SSc fibroblasts in the
context of a three-dimensional culture system, as knock-
down of the TSP1 gene or a blocking anti-TSP1 peptide,
which prevents activation of latent TGFb, reduced the
cell contractility of fibrotic SSc fibroblasts. In parallel,
antagonising TSP1 impaired expression of a-SMA,
integrin a3, and integrin b5. Blocking TSP1 expression
and activity also reduced the basal contractility of nor-
mal fibroblasts. We have found that endogenous TGFb
signalling contributes to the basal contractility of normal
and SSc fibroblasts in three-dimensional FPCL. The
r e s u l t sf r o mo u rc u r r e n tr e p o r ti n d i c a t et h a ti n c r e a s e d
activation of latent TGFb by TSP1 contributes to the
overall activity of exogenous TGFb during the process
o fE C Mc o n t r a c t i o ni nat h r ee-dimensional culture.
After mechanical loading of fibroblasts within the FPCL
system, TGFb activity and TSP1 expression were
increased. All these results indicate that TSP1 contri-
butes to the contractile ability of fibroblasts by promot-
ing myofibroblast differentiation by TGFb. Our data are
also consistent with the notion that TSP1 is a key med-
iator contributing to the enhanced contractile ability dis-
played by lesional SSc dermal fibroblasts. In summary,
blocking TSP1 may be a viable antifibrotic strategy.
The ability of TGFb1 to induce TSP1 in fibroblasts is
ERK dependent [42]. TSP1 can also induce ERK phos-
phorylation via b1 integrin [43]. Prior data from our
laboratory have shown heparan sulfate-dependent ERK
activation contributes to the enhanced contractile ability
demonstrated by lesional dermal scleroderma fibroblasts
[7]. Consistent with these results, in the current study we
have shown that anti-TSP1 strategies not only reduced
fibroblast contractility but also decreased ERK activation
in fibroblasts subjected to ECM contraction and mechan-
ical loading. We have also shown that TGFb and PDGF-
induced contractility in normal and SSc fibroblasts
corresponded with elevated expression of TSP1 and ERK
activation. It has been shown that TSP1 can bind and sta-
bilise PDGF, enhancing the biological effect of PDGF in
proliferative tissue repair [39]. It is interesting to note
that the overexpression of TSP1, whether induced by
TGFb and PDGF in normal fibroblasts or basally in SSc
Figure 6 The overexpression of thrombospondin 1 (TSP1) in
systemic sclerosis (SSc) fibroblasts is dependent on
endogenous transforming growth factor (TGF)b and platelet-
derived growth factor (PDGF) via mitogen-activated protein
kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)
activation. SSc fibroblasts were pretreated with SB431542 (activin-
linked kinase 5 (ALK5) inhibitor), U0126 (ERK inhibitor), interferon
(IFN)b or Gleevec (PDGF receptor inhibitor) overnight, prior to
determining TSP1 gene and protein expression. (a) Western blotting
showing that SB431542, U0126, Gleevec and IFNb inhibited the
overexpression of TSP1 protein in SSc fibroblasts. (b) The mRNAs of
fibroblasts in these treated samples were also assayed by reverse
transcription (RT)-PCR.
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ERK inhibitor (U0126). All these results indicate that, as
an endogenous activator of TGFb,T S P 1c o n t r i b u t e st o
the pathological contractile activity of SSc fibroblasts.
Moreover, TSP1 may also potentially mediate responses
to PDGF in the pathogenesis of SSc. Our results are
consistent with a previous suggestion that constitutive
overexpression of TSP1 in SSc fibroblasts depends on
autocrine TGFb signalling [9].
Lesional SSc dermal fibroblasts overexpress syndecan
4, CCN2 and TSP1 [7,9,10]. CCN2 is expressed by
mesenchymal cells undergoing active tissue remodelling,
and is characteristically overexpressed in connective tis-
sue pathologies such as fibrosis and cancer [6,44].
Heparan sulfate chains of syndecan 4 mediate response
to growth and differentiation factors such as TGFb [45].
Syndecan 4 also binds CCN and acts as a coreceptor for
CCN2 [46]. Although the precise nature of the interac-
tions among syndecan 4, CCN2 and TSP1 is still
unclear, our previous investigations found low expres-
sion of TSP1 in fibroblasts isolated from syndecan 4 -/-
or CCN2 -/- mice [11,47]. In our current study, TSP1
knockdown with siRNA did not alter expression of syn-
decan 4 and CCN2. Collectively, these results suggest
expression of TSP1 in fibroblast culture is downstream
of both syndecan 4 and CCN2. It has been reported
that, in a mouse model of arthritis, injection of TSP1
blocking peptides for 16 days reduced joint infiltration
and inflammation and CCN2 message and protein levels
[9]. However, this reduced CCN2 could result indirectly
due to the ability of TSP1 to activate latent TGFb.
Alternatively, a mechanism involving activation of cell
types other than fibroblasts might be involved. There-
fore, whether TSP1 directly affects CCN2 expression in
vivo in SSc still needs to be investigated.
We have previously shown that the ras/MEK/ERK
‘classical’ MAP kinase cascade is important for several
features of fibrogenesis. For example, MEK/ERK med-
iates the induction of CCN2 expression in normal
mesenchymal cells [48,49]. In addition, MEK/ERK is
required for a-SMA stress fibre assembly, via a synde-
can 4-dependent mechanism [7,10]. Moreover, the
enhanced constitutive ERK activation in lesional SSc
fibroblasts is due to an increase in syndecan 4 expres-
sion [7,10]. The MEK-ERK pathway and HSPGs contri-
bute to the overexpression of profibrotic proteins and
enhanced contractile forces in SSc dermal fibroblasts,
and the procontractile signals from TGFb are integrated
through syndecan 4 and MEK/ERK [11]. TGFb has long
been hypothesised to be a major contributor to patho-
logical fibrotic diseases [41]. In this investigation
we showed that TSP1-mediated TGFb activation con-
tributes to the pathological contractile activity of
SSc fibroblasts via an ERK-dependent mechanism. In
contrast, as a multifunctional cytokine, TGFb is not
only a key regulator of extracellular matrix assembly
and remodelling but also affects a wide variety of cellu-
lar processes. Therefore, therapeutic strategies focusing
on non-specific, systemic blockade of TGFb ligand-
receptor interactions may have a problematic side
effect profile considering the complex function of TGFb
in vivo [41]. Conversely, TSP1 is a multicellular protein
that modulates cell functions and cell-matrix interac-
tions [50]. Abnormalities observed in TSP1-null animals
resemble those observed in TGFb1 deficient animals,
but are much less severe [51]. Collectively, our results
suggest that, as compared to broad targeting of TGFb,
TSP1 may be an ideal therapeutic target for fibrotic
diseases such as SSc.
Conclusions
In summary, in this report we provide useful informa-
tion to further understand the mechanism underlying
extra cellular matrix contraction by fibroblasts and exag-
gerated TGFb signalling in the pathogenesis of SSc. Our
results could also prove to be a great advantage as a
potential therapy for disorders characterised by the
enhanced activity of TGFb in fibrotic disorders such
as SSc.
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